Glaukos Analyst Ratings
Ensign Group Analyst Ratings
RadNet Analyst Ratings
Alkermes Analyst Ratings
JP Morgan Maintains Neutral on Alkermes, Lowers Price Target to $31
Morgan Stanley Raises Price Target on Glaukos to $120 From $100, Keeps Equalweight Rating
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Centene (CNC) and Radnet (RDNT)
RadNet Analyst Ratings
Glaukos Analyst Ratings
Barclays Remains a Hold on Radnet (RDNT)
Stifel Nicolaus Remains a Buy on Krystal Biotech (KRYS)
Merit Medical Systems Poised for Growth: Operational Efficiency and Strategic Product Developments Fuel Buy Rating
Hold Rating on Merit Medical Systems Amid Mixed Financial Impact of EsophyX Z+ Acquisition
Merit Medical Systems Analyst Ratings
Buy Rating Affirmed for Merit Medical Systems Following Strategic EsophyX Z+ Acquisition
Ensign Group Analyst Ratings
Macquarie Initiates Ensign at Outperform With $134 Price Target
Merit Medical Systems Analyst Ratings
Needham Raises Price Target on Glaukos to $131 From $113, Maintains Buy Rating
Prestige Consumer Analyst Ratings